An Open-label Phase 1b Study to Evaluate the Safety and Efficacy of CCX872-B in Patients With Pancreatic Adenocarcinoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 17 Oct 2017
At a glance
- Drugs CCX 872 (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors ChemoCentryx
- 17 Oct 2017 Planned End Date changed from 1 Oct 2017 to 1Dec 2017.
- 17 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Nov 2017.
- 02 May 2017 Planned End Date changed from 1 Apr 2017 to 1 Oct 2017.